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Ubiquitin–proteasome system (UPS) is a primary signaling pathway for regulation of
intracellular protein levels. E3 ubiquitin ligases, substrate-specific members of the UPS,
represent highly attractive protein targets for drug discovery. The importance of E3
ligases as prospective targets for small molecule modulation is reinforced by ever
growing evidence of their role in cancer and other diseases. To date the number of
potent compounds targeting E3 ligases remains rather low and their rational design
constitutes a challenging task. To successfully address this problem one must take into
consideration the multi-subunit nature of many E3 ligases that implies multiple druggable
pockets and protein–protein interfaces. In this review, we briefly cover the current state
of drug discovery in the field of RING-type E3 ligases with focus on MDM and Cullin
families as targets. We also provide an overview of small molecule chimeras that induce
RING-type E3-mediated proteasomal degradation of substrate proteins of interest.
Keywords: ubiquitin–proteasome system, RING-type E3 ligases, MDM family, Cullin family, small molecules,
induced protein degradation, PROTACs, SNIPERs
INTRODUCTION
In the last two decades, scientists around the globe paid increasing attention toward UPS, a primary
pathway for regulation of protein turnover and removal of misfolded proteins in eukaryotic cells.
The molecular mechanism of proteasomal protein degradation is driven by a consecutive action
of three enzyme categories (E1 activating, E2 conjugating, and E3 ligating) that covalently tag
substrate proteins with a chain of ubiquitins, small regulatory proteins (Hershko and Ciechanover,
1998; Pickart, 2001). Subsequent fate of the substrate is defined depending on type of ubiquitin
linkage, its length and post-translational modifications. UPS operates in nucleus and cytoplasm,
which enables ubiquitin-mediated regulation of cell cycle control, DNA damage response, innate
immunity, and proteasomal protein degradation.
Abbreviations: ABL, Abelson tyrosine-protein kinase; AR, androgen receptor; BCR, breakpoint cluster region protein;
BET, bromodomain and extra-terminal domain; BRD2, bromodomain-containing protein 2; cIAP1, cellular inhibitor of
apoptosis protein 1; CRABP-II, cellular retinoic acid binding protein-II; CRL, cullin RING E3 ligase; ERα, estrogen receptor
α; FANC, Fanconi anemia ligase; HIF1α, hypoxia-induced factor 1-α; IAP, inhibitor of apoptosis protein; MDM2, murine
double minute 2; NAE, NEDD8-activating enzyme; NEDD8, neural precursor cell expressed developmentally down-regulated
protein 8; NOTCH1, neurogenic locus notch homolog protein 1; PDE4, cAMP-specific 3′,5′-cyclic phosphodiesterase 4; POI,
protein of interest; PROTAC, proteolysis-targeting chimera; RBR, RING-between RING-RING; RING, really interesting new
gene; SARM, selective androgen receptor modulator; SNIPER, specific and non-genetic IAP-dependent protein erasers; UPS,
ubiquitin–proteasome system; VHL, von Hippel-Lindau; XIAP, X-linked inhibitor of apoptosis protein.
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E3 ligases confer substrate specificity of the whole UPS
and function via two primary mechanisms – they can play
an intermediary catalytic role in transfer of ubiquitins from
E2∼Ub conjugate to the substrate or, alternatively, facilitate
direct ubiquitin transfer bypassing the E3 ligase itself. The first
mechanism is common for Homologous to E6-AP Carboxy
Terminus (HECT)-type E3s, whereas the second one is typical
for RING-type E3s.
Initially the RING domain was identified in RING1 protein
and later confirmed to be a structural element of Rbx1
that functions as E2-recruiting subunit of E3 ligase (Kamura
et al., 1999; Ohta et al., 1999; Seol et al., 1999; Tan
et al., 1999). The canonical RING finger motif can be
represented as Cys-X2-Cys-X(9−39)-Cys-X(1−3)-His-X(2−3)-Cys-
X2-Cys-X(4−48)-Cys-X2-Cys, where X is any other amino acid
(Deshaies and Joazeiro, 2009). The domain includes two Zn2+-
coordinated loops and intervening central α-helix that together
form a conserved structural platform for anchoring the E2
conjugating enzyme.
RING E3s can be categorized according to the form of
subunit organization: (1) mono-subunit ligases like MDM
and Cbl; (2) multi-subunit complexes such as CRL, anaphase
promoting complex/cyclosome (APC/C) (Castro et al., 2005)
and FANC (Metzger et al., 2014). Another important RING
family members are RBRs, the single subunit enzymes with
multiple RING domains (Spratt et al., 2014). In addition,
worth mentioning are U-box ligases, containing atypical RING
domains without coordinated Zn2+ ions, that are often featured
as separate from canonical RING E3s (Hatakeyama et al.,
2001).
Notably, E3 ligases were proposed to become the “new
kinases” owing to the significant therapeutic and market potential
of their small molecule inhibitors (Cohen and Tcherpakov, 2010).
Recent advances demonstrated that E3s in general, and MDM
and Cullin families (Figures 1A,B), in particular, have captured
significant attention of the research community due to their key
role in poly-ubiquitination of substrate proteins (Maniaci et al.,
2017).
Here, we briefly highlight members of MDM and CRL families
of RING-type E3 ligases, their primary functions and small
molecule modulation.
MDM FAMILY – MDM2 AND MDM4
MDM family includes MDM2 and its homolog MDM4
(also known as MDMX). Both enzymes are overexpressed
in many cancers and function as key negative regulators
of oncosuppressor protein p53 that is often referred to as
“guardian of the genome” (Haupt et al., 2017). MDM2-MDM4-
p53 signaling circuit regulates core metabolic pathways that
involve DNA damage response, induction of apoptosis, cell
cycle arrest, and senescence. In nearly half of cancers p53 is
downregulated due to overexpression of MDM2 or/and MDM4,
while the other half is caused by tumorigenic missense mutations
of p53, mostly occurring in DNA-binding domain (Muller and
Vousden, 2013).
MDM2 binds wild-type p53 with high affinity, blocks its
transcriptional activator functions and regulates its nuclear
export, stability, intracellular levels (Geyer et al., 2000). MDM4
shares a high structural homology with MDM2, mainly in the
N-terminal p53-binding domain, yet due to low E3 ligase activity
its overexpression does not lead to dramatic p53 downregulation
(Huang et al., 2011). Interaction of MDM2 and MDM4 via
their RING domains results in formation of MDM2/MDM4
hetero-dimeric complex that enhances p53 ubiquitination and
degradation (Pant et al., 2011).
Many therapeutic strategies based on disrupting p53/MDM2
protein–protein interaction are aimed to stabilize and activate
p53 in order to initiate programmed cell death in cancers
with overexpressed MDM2 (Zhang et al., 2015). Numerous
examples of MDM2 inhibitors include small synthetic
molecules such as Nutlin-3a (Vassilev et al., 2004), RG7112
(Vu et al., 2013), NU8231 (Hardcastle et al., 2011), MI773
(Zhao et al., 2013), CGM097 (Holzer et al., 2015) with several
others already in clinical trials as drug candidates (Tisato
et al., 2017) (Figure 1A). Development of potent MDM2
inhibitors remains a longstanding mainstream in the p53 field,
meanwhile the importance of therapeutic targeting MDM4
was recognized later. To date a certain progress was achieved
in development of p53/MDM4 inhibitors such as SJ-172550
(Reed et al., 2010; Bista et al., 2012), WK298 (Popowicz
et al., 2010) and stabilized peptide SAH-p53-c8 (Bernal et al.,
2010).
In addition, simultaneous inhibition of both MDM2 and
MDM4 enzymes, i.e., by means of dual inhibitors, was proposed
to enhance p53 activation (Hu et al., 2007; Popowicz et al., 2010;
Zaytsev et al., 2015). Stapled peptide ALRN-6924 (Aileron, Inc.)
is an example of dual inhibitor that is currently undergoing
clinical trials against solid tumors and lymphomas (Chang et al.,
2013). Also, worth mentioning an approach based on targeting
MDM2/MDM4 interface with short peptides that initiate p53-
induced apoptosis and slowdown of tumor growth (Pellegrino
et al., 2015).
CULLIN FAMILY – CULLIN RING E3
LIGASES (CRLs)
Cullin RING E3 ligases constitute the largest family of E3 ligases
with over 200 known members (Sarikas et al., 2011). In certain
cell types up to 20% of the proteasomal protein degradation
is mediated by CRLs (Soucy et al., 2009). Classification of
CRL family is based on type of Cullin scaffold serving
as a backbone of the multi-subunit protein complex. The
evolutionary conserved Cullin protein has several forms that
share structural similarity – Cul1, Cul2, Cul3, Cul4A, Cul4B,
Cul5, and Cul7. Accordingly, the resulting E3 ligases are named
CRL1-CRL7. Some classifications also include Cul9 known as
p53-associated parkin-like cytoplasmic protein (PARC) (Li and
Xiong, 2017).
Assembly of the multi-subunit CRLs was originally reported
for the archetypal Skp1-Cul1-Rbx1 complex (Feldman et al.,
1997). The CRL structure is based on modular organization of
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FIGURE 1 | Structural organization of (A) MDM and (B) CRL RING-type E3 ubiquitin ligases and a brief list of their most potent modulators. MDM2 and MDM4 are
single subunit proteins containing C-terminal RING finger domain. In contrast, CRLs are constituted of several subunits, such as receptor, adaptor, Cullin scaffold
and RING-box protein. (C) Schematic representation of PROTAC/SNIPER molecule acting to induce ubiquitination and subsequent proteasomal degradation of
substrate protein of interest. These small molecule degraders contain substrate-specific component, short linker, and E3-specific component.
constituent subunits such as substrate receptors (F-box, SOCS-
box, DCAF, and BTB), adaptors (Skp1, ElonginB, ElonginC,
DDB1, and BTB), Cullin scaffolds (Cul1-Cul7 and Cul9) and
RING finger proteins (Rbx1 and Rbx2). The wide range of
building blocks and their combinations enables formation of a
multitude of functionally diverse E3 ligases (Bosu and Kipreos,
2008; Sarikas et al., 2011; Lydeard et al., 2013). Full-size CRLs
are notoriously difficult to obtain and characterize, to date only
several complexes containing a complete set of subunits were
reported, including SOCS2-EloB-EloC-Cul5-Rbx2 (Bulatov et al.,
2015), VHL-EloB-EloC-Cul5-Rbx1 (Cardote et al., 2017), Skp2-
Skp1-Cul1-Rbx1 (Zheng et al., 2002), DDB2-DDB1-Cul4A-Rbx1
(Fischer et al., 2011).
Drug discovery in the CRL field keeps advancing, driven by
foreseeable role of these enzymes as targets in numerous human
diseases (Petroski, 2008; Cohen and Tcherpakov, 2010; Andérica-
Romero et al., 2013; Zhao and Sun, 2013). The CRLs as drug
targets are promising, yet highly sophisticated due to diverse
putative combinations of structural components that result in
multiple protein–protein interfaces.
The growing number of reported CRL crystal structures
includes full-size enzymes, individual components and their
complexes. Here, particularly important are structures of
receptor subunits with bound small molecules because they
provide crucial information for rational design of potent
modulators. Examples (Figure 1B) include Probe 8, auxin-mimic
that disrupts interaction between TIR1 (receptor in CRL1TIR1)
and its substrate Aux/IAA (Hayashi et al., 2008); VL111, Ligand 7
and their enhanced analog VH298 that inhibit binding of VHL
protein (receptor in CRL2VHL) to substrate hypoxia-inducible
factor 1-alpha (HIF1α) (Buckley et al., 2012; Galdeano et al., 2014;
Soares et al., 2018); thalidomide and its derivatives lenalidomide,
pomalidomide that modulate CRL4ACRBN activity by binding to
its CRBN receptor subunit (Chamberlain et al., 2014; Fischer
et al., 2014).
Targeting CRLs for therapeutic applications is obstructed
by several factors. Firstly, there is no general approach and
each enzyme has to be tackled individually according to its
structural and functional characteristics. Secondly, CRLs are
complex molecular entities assembled from several independent
subunits that form a number of protein–protein interfaces and
druggable pockets. Surprisingly, the apparent complexity of this
multi-subunit system might turn out to be an advantage –
the multitude of interfaces and pockets provides additional
opportunities for design of specific binders (Bulatov and
Ciulli, 2015). Small molecules modulate CRL activity directly
by inhibiting substrate/receptor interaction, disrupting CRL
assembly, inducing allosteric conformational shifts that lead
to suppressed activity or altered ensemble dynamics (Lee and
Craik, 2009). In some cases modulators stabilize specific protein–
protein interactions within the CRL complex (Thiel et al., 2012).
RING-TYPE E3 LIGASES AS TARGETS
FOR DRUG DISCOVERY
Drug discovery in the UPS field thrived since FDA approval
of 26S proteasome inhibitors Bortezomib (approved in 2003,
marketed as Velcade R©) and more recently Carfilzomib (approved
in 2012, marketed as Kyprolis R©) for treatment of multiple
myeloma. Although proteasome inhibitors demonstrate
selectivity toward tumor cells and lead to apoptosis, they also
suppress proteasome-mediated degradation of all intracellular
proteins resulting in potential side effects (Shibata et al., 2018).
In addition to that, many patients were demonstrated to
develop resistance toward Bortezomib that acts as a reversible
competitive inhibitor of 26S proteasome (Ohoka et al., 2018).
Strategies to overcome the resistance include design of inhibitors
with alternative mechanism of action, i.e., Carfilzomib covalently
binds proteasome and causes its irreversible inhibition.
Another emerging and highly promising strategy is to
target different levels of ubiquitination cascade upstream of
proteasome, mainly E1, E2, and E3 enzymes (Shibata et al.,
2017). Here, E3 ligases determine substrate specificity and,
therefore, represent primary molecular targets for small molecule
modulation. Development of potent E3 ligase modulators is risky
and challenging task complicated by diverse protein–protein
interfaces of the multi-component complexes, lack of a classical
enzymatic/catalytic active site and specificity problems stipulated
by a variety of potential substrates.
RING-type E3 ligases were previously successfully targeted
using small molecule inhibitors of protein–protein interactions,
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i.e., binding at substrate/receptor HIF1α/VHL (Ohoka et al.,
2017b), p53/MDM2 and p53/MDM4 interfaces (Ohoka et al.,
2017a), adaptor/receptor interface Skp1/Skp2 (Chen et al., 2008)
and several other, as reviewed in Bulatov and Ciulli (2015).
In addition, it would be reasonable to mention an auxiliary
protein NEDD8 that serves as crucial regulator of CRL
functions (Soucy et al., 2009). The ubiquitin-like protein
NEDD8 gets covalently conjugated to a specific conserved
lysine residue at C-terminal domain of Cullin scaffold in a
process termed NEDDylation. NEDD8 conjugation enhances
substrate ubiquitination by promoting CRL dynamics and
inducing conformational shift of the protein ensemble that
brings together E3-bound substrate and Rbx–E2∼Ub (Duda
et al., 2008, 2011). In addition, MDM2 was demonstrated
not only to autoNEDDylate itself, but also to mediate p53
NEDDylation that inhibits its transcriptional activity (Xirodimas
et al., 2004). Pevonedistat (also known as MLN4924), a first-
in-class selective inhibitor of NEDD8-activating enzyme (NAE)
that mediates NEDDylation, is currently undergoing several
clinical trials against different types of cancer (Swords et al.,
2015).
TARGETED PROTEIN DEGRADATION
MEDIATED BY RING-TYPE E3 LIGASES
A novel paradigm-shifting approach that dramatically increases
the attractiveness of E3 ligases as targets for drug design is
based on proteolysis-targeting chimeras (PROTACs) (Buckley
and Crews, 2014; Lai and Crews, 2017). These are hetero-
bifunctional compounds with bivalent selectivity, they consist of
three key elements: substrate-specific component (“warhead”),
short linker, and E3-specific component. PROTACs bind and
bring into close proximity substrate protein of interest (POI)
and E3 ligase thus facilitating E3-mediated ubiquitination of
the substrate (Figure 1C). This approach, sometimes called as
“chemical knockdown,” enables ligand-induced degradation of
specific endogenous proteins (Bondeson et al., 2015).
Historically the first small-molecule-based PROTAC degrader
was developed for recruiting MDM2 E3 ligase by Nutlin-
3a imidazoline derivative, as reported by Crews laboratory
(Schneekloth et al., 2008). In this study androgen receptor (AR)
was targeted by SARM compound connected to Nutlin-3a moiety
via PEG-based linker. Treatment of AR-expressing HeLa cells
with SARM-Nutlin-3a bivalent molecule resulted in depletion
of AR levels. Since then there were no subsequent reports of
MDM2-mediated PROTACs, though given the large and still
expanding repertoire of potent MDM2 inhibitors it would be
reasonable to expect much higher interest in such degraders.
CRL2VHL is the most prominent example of E3 ligase
directed by PROTACs to ubiquitinate a recruited substrate
protein and result in its proteasomal degradation. The E3-
specific component is designed to mimic HIF1α, natural
substrate of VHL receptor, post-translationally hydroxylated
at prolines 402 and/or 564. Examples of proteins selectively
targeted by PROTACs via CRL2VHL-mediated mechanism
include BET family of epigenetic regulators BRD2, BRD3, and
BRD4 (Zengerle et al., 2015; Raina et al., 2016; Gadd et al.,
2017; Zhou et al., 2017; Chan et al., 2018), steroid hormone
receptor ERRα and serine-threonine kinase RIPK2 (Bondeson
et al., 2015). Another recent study demonstrated successful
degradation of oncogenic tyrosine kinase BCR-ABL using
both CRL2VHL- and CRL4ACRBN-specific PROTACs (Lai
et al., 2016). Here, FDA-approved tyrosine kinase inhibitors
Bosutinib and Dasatinib served as PROTAC “warheads,”
whereas hydroxy-proline derivative and pomalidomide were
used as CRL2VHL- and CRL4ACRBN-binding components,
respectively. Similarly, PROTAC-directed CRL4ACRBN-mediated
target degradation also includes BRD4 and cytosolic protein
FKBP12 (Lu et al., 2015; Winter et al., 2015). In addition,
Ciulli laboratory recently reported curious example of
the first homo-bivalent PROTAC (Homo-PROTAC) that
simultaneously recruits two CRL2VHL molecules and induces
their suicidal self-degradation (Maniaci et al., 2017). Highly
potent Homo-PROTAC CM11 contains two molecules of
the previously described VH298 compound connected via
polyethylene glycol linker (Frost et al., 2016; Soares et al.,
2018).
SNIPERs, an abbreviated form of specific and non-genetic
IAP-dependent protein erasers, are a class of small-molecule
degraders similar to PROTACs (Itoh et al., 2010, 2011). These
compounds recruit IAP family of RING-type E3 ligases – cIAP1,
cIAP2, and XIAP. The SNIPER chemical structure consists
of selective IAP antagonist (i.e., Bestatin, MV1, and LCL161),
PEG linker and peptide- or small-molecule-based POI-specific
component. The initial concept was further explored by Naito
laboratory that recently demonstrated selective proteasomal
TABLE 1 | List of substrate proteins targeted by PROTACs and SNIPERs for
RING-type E3-mediated proteasomal degradation.
Substrate RING-type E3 ligase Reference
PROTACs
AR MDM2 Schneekloth et al.,
2008
BRD2, BRD3, BRD4 CRL2VHL Thiel et al., 2012;
Zengerle et al., 2015;
Raina et al., 2016;
Gadd et al., 2017;
Chan et al., 2018
ERRα, RIPK2 CRL2VHL Bondeson et al., 2015
VHL CRL2VHL Maniaci et al., 2017
BCR-ABL CRL2VHL, CRL4ACRBN Lai et al., 2016
FKBP12 CRL4ACRBN Winter et al., 2015
BRD4 CRL4ACRBN Lu et al., 2015; Winter
et al., 2015
SNIPERs
AR cIAP1/cIAP2/XIAP Shibata et al., 2018
ERα Ohoka et al., 2018
BCR-ABL Shibata et al., 2017
BRD4 Ohoka et al., 2017b
PDE4 Ohoka et al., 2017b
NOTCH1 Ohoka et al., 2017a
CRABP-II Okuhira et al., 2011
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degradation of a range of substrate proteins, including ERα
(Ohoka et al., 2018), BCR-ABL (Shibata et al., 2017), BRD4 and
PDE4 (Ohoka et al., 2017b), NOTCH1 (Ohoka et al., 2017a),
CRABP-II (Okuhira et al., 2011).
These examples, listed in Table 1, illustrate that induced
protein depletion mediated by small molecule degraders
(PROTACs and SNIPERs) specific for certain RING-type E3
ligases (MDMs, CRLs, and IAPs) is a justified paradigm for
drug discovery. These compounds operate in sub-stoichiometric
manner and catalyze enzymatic removal of substrate POIs
(chemical knockdown) rather than their inhibition via
binding site occupation. The PROTAC/SNIPER-based approach
counteracts restoration of intracellular POI levels and is seen as a
promising addition to conventional gene knockdown techniques
(i.e., RNAi, antisense oligonucleotides, and CRISPR/Cas9)
(Crews, 2018).
CONCLUSION
Many E3 ubiquitin ligases are implicated in cellular physiology
and homeostasis at multiple regulatory levels, play crucial roles
in a wide range of human diseases, including cancer and
inflammatory disorders. The RING-type ligases represent the
largest class of E3s in humans and are responsible for recognition,
poly-ubiquitination and subsequent proteasomal degradation
of numerous substrate proteins. Given the structural intricacy
of RING-type E3s and their diverse functions it is essential
to understand molecular principles that govern assembly
and interactions of subunits within the protein complex.
We anticipate a forthcoming re-focusing of research efforts
from structural/functional characterization of these enzymes
to rational design of precision molecular tools capable of
modulating E3 activity in living cells and organisms. One could
envisage that targeted therapeutic action upstream of proteasome
could potentially lead to emerging resistance caused by feedback-
driven compensatory mechanisms. This could potentially be
overcome by administering a synergistic combination of drugs
that act via distinct molecular mechanisms.
The MDM and CRL families of RING-type E3s are growing in
importance as attractive targets for small molecule therapeutics
that could operate not only as inhibitors but also activators of
enzymatic activity, disruptors and stabilizers of protein–protein
interactions, regulators of protein dynamics. The availability of
X-ray structural data, especially for full-size enzymes, remains
to be one the main limitations for structure-based design of
modulators for multi-subunit E3 complexes. Nevertheless, slow
yet steady increase of solved crystal structures of RING-type
E3s and their ligand-bound complexes provides opportunities
for further rational design of highly potent modulators.
General strategies for discovery of novel E3 modulators include
in vitro screening of compound libraries using functional
assays (i.e., ubiquitination assay) (Sun, 2005); software packages
(i.e., ICM-Pocket Finder) predicting druggable pockets for
subsequent in silico ligand screening and docking (Cardozo and
Abagyan, 2005); fragment-based discovery and rational structure
elaboration (Van Molle et al., 2012; Gadd et al., 2015).
In addition, PROTAC/SNIPER-induced ubiquitination and
intracellular degradation of specific substrates offers an added
layer of specificity and constitutes an emerging strategy for
post-translational regulation of protein levels. These compounds
demonstrate high potential for a novel modality of chemical
intervention on UPS and hold much promise as prospective
therapeutic candidates. Such chemical protein knockdown
technologies based on RING-type E3 modulation still remain
largely untapped by the pharmaceutical industry, however, it is
reasonable to expect a major progress in this direction in near
future.
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